MorphoSys AG American Depositary Shares - MOR STOCK NEWS

MorphoSys AG has released its financial calendar for 2023, detailing key dates for financial reports and conference calls. Notable dates include:

• March 15, 2023: Year-End Results 2022
• May 3, 2023: First Quarter Interim Statement
• August 9, 2023: Half-Year Report
• November 15, 2023: Third Quarter Interim Statement
• May 17, 2023: Annual General Meeting

The company aims to advance cancer treatment through innovative biopharmaceutical solutions.

MorphoSys AG (NASDAQ: MOR) reported Q3 2022 net product sales of Monjuvi at US$ 22.2 million, a slight increase from US$ 22.0 million in Q3 2021. Total revenues soared to € 95.8 million, up from € 41.2 million in the same period last year, reflecting higher license revenues. However, the consolidated net loss widened to € 122.9 million. R&D expenses increased to € 77.8 million, attributable to ongoing clinical programs. Cash and financial assets totaled € 1,038.1 million as of September 30, 2022.

MorphoSys AG announced that the GRADUATE I and II studies, partnered with Roche, did not meet their primary endpoint of slowing clinical decline in patients with early Alzheimer's disease. The studies evaluated gantenerumab, which showed lower than expected beta-amyloid removal. Despite this setback, gantenerumab was well tolerated during the trial. The Phase 3 program involved 1,965 participants over 27 months. The topline findings will be presented at the CTAD Conference on November 30, 2022.

MorphoSys AG (FSE:MOR, NASDAQ:MOR) will release its Q3 and 9-month 2022 financial results on November 16, 2022, at 10:00 pm CET. A conference call will be held the following day, November 17, 2022, at 2:00 pm CET, featuring a management presentation and a Q&A session. The event will provide insights into their financial performance and outlook for 2022. Investors can access a live webcast and presentation on the company’s website and participate via phone by pre-registering for dial-in details. A replay will be available post-event.

MorphoSys U.S. Inc. announced new data presentations at the 64th American Society of Hematology (ASH) Annual Meeting, showcasing pelabresib for myelofibrosis and tafasitamab for diffuse large B-cell lymphoma (DLBCL). The data, featured in 14 presentations, includes findings from pivotal studies MANIFEST-2 and frontMIND, emphasizing the therapies' potential to enhance treatment for challenging blood cancers. Tim Demuth, Chief Research and Development Officer, highlighted the commitment to improving first-line treatment options and showcased the quality of ongoing research.

MorphoSys AG announced preliminary results from the Phase 1/2 trial of tulmimetostat (CPI-0209) in heavily pretreated cancer patients, showing responses in several tumor types. Data presented during the 34th EORTC-NCI-AACR Symposium indicated disease stabilization in cohorts including metastatic prostate cancer and endometrial carcinoma. At the July 16, 2022 cutoff, 51 of 52 patients were treated, with notable responses in ovarian cancer and mesothelioma. Safety evaluation revealed common adverse effects like thrombocytopenia and diarrhea. These findings support further investigation into tulmimetostat's therapeutic potential.

MorphoSys AG announced an update regarding its licensing partner GSK and the ContRAst phase III program for otilimab, aimed at treating moderate to severe rheumatoid arthritis. The trials ContRAst-1 and ContRAst-2 successfully met primary endpoints, showing significant ACR20 responses. However, ContRAst-3 did not meet its primary endpoint, leading GSK to conclude that otilimab does not present a suitable benefit/risk profile for regulatory submission. GSK plans to publish the full results in 2023.

MorphoSys reported preliminary U.S. net product sales of Monjuvi at US$ 22.2 million for Q3 2022, totaling US$ 64.1 million for the first nine months. The company has revised its full-year sales guidance for Monjuvi to approximately US$ 90 million, down from US$ 90 to US$ 110 million, due to increased competition in the treatment of diffuse large B-cell lymphoma. The gross margin for Monjuvi remains at 75% to 80%. Full financial results will be released on November 16, 2022.

MorphoSys U.S. Inc. has presented findings from the L-MIND study at the Tenth Annual SOHO Meeting, showcasing the long-term efficacy of Monjuvi (tafasitamab-cxix) combined with lenalidomide in patients with relapsed or refractory DLBCL. At the February 15, 2022 cutoff, 34% of patients completed at least 2 years of therapy, with a median duration of 4.3 years. Notably, 23 out of 27 patients were alive, and adverse events decreased upon transitioning to monotherapy. This data underlines Monjuvi's significance as a viable treatment option.